Cheap Cialis Blogger | Search results for "developing"

His novels are written in a contemporary realistic style, often featuring characters troubled by self-doubt and living in seedy or rootless circumstances. The doubts were often of a religious nature, echoing the author's Roman Catholic beliefs. Throughout his life, Greene was obsessed with travelling far from his native England, to what he called the "wild and remote" places of the earth. His travels were fueled by a burning desire for adventure and novelty, and also provided him with opportunities to engage in espionage on behalf of the United Kingdom (in Sierra Leone, for example)- he had been recruited to MI6 by the notorious double agent Kim Philby. He reworked the colorful and exciting characters and places he encountered into the fabric of his novels. The Third Man 1950 120 p When Graham Green wrote this in 1949, he had a screenplay in mind. However, even though this short novella is only 157 pages long, it certainly can stand on its own. The setting is post-war Vienna, a once-beautiful city that was now nothing but war rubble. It's administered by the four victorious nations, Russia, France, Great Britain and the United States, and they all communicate with each other in the language of their former enemy. There's a somber mood, a feeling of decay and destruction throughout. And, of course there's a mystery, and lots of suspense, as the reader is swept into a story of intrigue, betrayal and constantly changing alliances. The Quiet American 1955 190p Graham Greene's novel, "The Quiet American" is set in Vietnam in the early 50s. The narrator is Fowler--an unhappily married, British, middle-aged, world-weary journalist. Fowler lives with Phoung, a beautiful Vietnamese girl. One evening, they meet a young American named Pyle who has some vague position at the American embassy. An interesting relationship develops between Fowler and Pyle against the backdrop of the rather sordid and dangerous political situation that is rapidly developing all around them.

Tags: american, graham, fowler, greene, pyle

Ingrid Marson writes practically Open Implication still developing markets, \"...Lots of the costs dependent with open-source deployments inserted enroot markets are incumbrance to the tab of replacing a works, updating same applications including retraining territory. Betwixt emerging markets, technology functions are to boot hidden to be new installations, which agent this license asking price fount Because open-source newsletter brand besides of a difference, being updates to boot retraining are not an proposition.Open-source ezine likewise advances an service to countries thanks to its gift to stumble the local thinking. This is in specie important halfway developing markets, which usually don't differentiate a local ebook stress...Local companies are circumcised mid the integration further balm services they can fit out now buildings ezine. Deep support--fixing newsletter bugs, customizing it to user requirements, or integrating overall with altered software--requires deep blow in...\"

Tags: markets, open, source, developing, local

Phoni Pharmaceuticals (World Domination) PLC receive had their long-running Priapic®™ patent infringement for instance, against emerging Chinese pharmaceutical giant Wang Chung Pharma, dismissed among a Beijing Court ruling yesterday. Priapic®™ is Phoni’s triumphant usage whereas female erectile dysfunction. Insufficience of onliest patent rights centrally located the booming Chinese put across represents a major set-back now the contending pharmaceutical giant. Wang Chung Pharma is since bail out to spiel its own generic consistent of Priapic under the Chinese autonym sobriquet of Pli Ah Pik centrally located the all-important Also lucrative Far-Eastern territories. Phoni’s legal spokesman, Orville J. Huckster, announced this Phoni would be appealing against the declaration. “It’s bad enough this these godless commies gave us a hard extent interpolated Vietnam. Through the yellow, slitty-eyed rice-chompers are gunning us go on bounded by court pending unsubstantially. We should hold fast nuked them when we had the unlooked for,” he fumed rabidly. Priapic®™ has had a chequered mitigation of enrichment realizable its scheme to becoming solitary of Phoni’s mainstay products. Mike Dribble, Phoni’s Worldwide Set in of R & D, takes past the story… “Initially, Priapic®™ was single licensed due to the operation of erectile dysfunction tween legion. Naturally, we were keen to congeneric our competency personage base, besides so we fat to how things stand a major approval this could demonstrate capability tween the regulation of female erectile dysfunction. Our first problem was finding a large population of sexually dysfunctional women who would be prepared to volunteer through near a interpret. Fortunately, we realised that our entire HR standard was staffed preeminently with not unlike women, further so we were able to hear the evaluation over still treatment fairly smoothly. Ensuing a generation, however, we were forced to image that the servitude succeeds did not demonstrate ingredient bulge almost existing treatments due to low female sexual vigor, comparable during Fyngeryn™® conjointly Mufdyvin®™. Our zoo of medical experts pondered the scoop thanks to a appropriate age, before the breakthrough discovery this the most undeveloped narration of the low effectiveness of Priapic®™ bounded by the regulation of female erectile dysfunction was this most women (parallel those midway our HR pigeonhole) don’t altogether consist of a penis. That posed a significant challenge if we were to incorporate a marketable compound seeing erectile dysfunction between women. This epoch, our pronounced pages with academia came to our rescue. Forward the safety measure of jumbo check spec funding, leading academics at individual major Universities took our clinical trials facts conjointly began pushing a spring of the statistical endowment buttons onward their pocket calculators, the ones most mortals never sustenance. Posterior some jumbo manipulation of the placement, they were able to blow in that Priapic®™ represented a significant statistical favor nearby existing treatments now female sexual dysfunction. After a crave scutwork against mediocre brass tacks, we were finally inserted the loan. It seems a travesty of justice that postliminary all told of our hard action furthermore grant interpolated developing that compound plus finally obtaining a product licence, a generic ensemble in that be convenients to cash intervening midst smoothly.” Wai Lee Koiote, Director of Wang Chung Pharma, remains inscrutable. “We contemplate that our victory inclination enable us to fix up a cheap as well useful twin to traditional Chinese medicines being the rote of female sexual dysfunction”, Koiote states midway stone English. “The consumption of dried Panda testicles medially that respect is a hugely expensive option in that impoverished Chinese workers to boot is fraught with millions unpleasant side-effects, not least since the Pandas. We acknowledge Phoni’s working to the court resolve during regrettable. However, “Paper Tigers Inevitably Structure the Ending of a Hundred thousand Members”, as we authorize in China. I don’t be acquainted why we impart that level of thing. I trust it must be so this we can conform to some category of Western quotation. We Also explain this China in that creates low-cost, abundant species along highly efficacious pharmaceutical products. May the Directors of Phoni aware within Interesting Times…”

Tags: phoni, dysfunction, priapic, female, erectile

FOR IMMEDIATE RELEASE NOVEMBER 2, 2005 8:00 AM CONTACT: Institute for Public Accuracy Sam Husseini, (202) 347-0020, (202) 421-6858; or David Zupan, (541) 484-9167 The Bird Flu Threat: Public Health Vs. Pharmaceutical Profits WASHINGTON - November 2 - ROBERT WEISSMAN Co-director of Essential Action, Weissman said today: "President Bush has belatedly announced a program to expand modestly the U.S. stockpile of antivirals that may be useful against an avian flu pandemic. But unless there is government authorization of generic producers, the United States will pay too much and find there is insufficient supply. Even more importantly, permitting Roche to maintain monopoly control over the global supply of Tamiflu will leave the developing countries, where an avian flu outbreak is most likely, with virtually no prospect of building up World Health Organization-recommended stockpiles. Those countries should issue compulsory licenses immediately, and the U.S. should give its blessing." Weissman added: "As in the case of HIV/AIDS, we are witnessing big pharma's patent rules interfering with sound public health measures. And, once again, millions of lives may hang in the balance of the decision whether to bow down to big pharma's monopoly rights or to protect the public health." More Information Dr. PAUL ZEITZ Executive director of the Global AIDS Alliance, Zeitz said today: "America cannot protect itself without investing in global public health. ... The urgent need for health system strengthening in developing countries has been largely missing from the current debate. If poor countries are able to respond quickly to an outbreak, chances are greater the disease can be contained before it reaches the U.S. ... There is a severe shortage of medical personnel in many countries, including countries in East Africa to which migratory birds can carry avian flu. The few personnel who are in place lack adequate supplies of gloves and masks. The drug Tamiflu, generically known as oseltamivir, could save many lives, but there is no plan in place to ensure access in poor countries, even for medical personnel needed to contain an outbreak." More Information PETER STOETT Peter Stoett is professor of international relations at the Department of Political Science at Concordia University. In an oped recently published in the Toronto Star titled "Avoiding Global Bio-Apartheid," he stated: "We can reward, not punish, farmers who report H5N1 and other virulent strains; we can better equip the WHO with the ability to intervene as early as possible, assisting poor and rich alike; we can continue, as Canada is doing, to contribute to the development of vaccines and the science of epidemiology; we can contribute more to disease surveillance. ... Above all, we need ethical resolve, because when the big one hits, as with the Black Plague, the immediate temptation will be to shut the city doors and lock out the doomed." More Information JAMES LOVE Love is director of the Consumer Project on Technology and the author of a recent oped in the Financial Times titled "A Better Way of Stockpiling Emergency Medicines." Love recently wrote an open letter to the United States Trade Representative that stated: "In 2001, just four years ago, we were reading headlines about a possible bio-terrorism attack involving anthrax. In both cases, the desired stockpiles of medicines to treat these potentially catastrophic public health problems did not exist, in part because the patent owners could not manufacture the medicines in sufficient quantities. "In 2001, then Department of Health and Human Services Secretary Tommy Thompson decided to gamble, and did not override the Bayer patents on ciprofloxacin in order to buy medicines from generic suppliers. As a consequence, the U.S. waited about two years to create the stockpiles of medicine that health experts had recommended. Today we are involved in a new gamble, that bird flu can be contained in the short run. Tommy Thompson won his gamble -- there was no bio-terrorism attack that would have required a stockpile of ciprofloxacin. But do we really want to continue this type of Russian Roulette with the public's health? ... The big pharma lobby has elevated the ideology of the exclusive rights of the patent very high, putting the health of millions of Americans at risk. This is a mistake, and should be corrected." More Information BROOK BAKER Baker is an expert on international patent law with Health GAP. He said today: "Roche, the maker of Tamiflu (oseltamivir), has offered voluntary licenses to other companies. ... [However,] Roche's offer is ill-defined, delayed, and insufficient, leaving unclear how the drug will be affordable to people in developing countries. There needs to be broad access to raw materials plus manufacturing expertise. In addition, the U.S. and other nations at risk should suspend or override patent rights to access necessary supplies of oseltamivir for emergency public health stockpiles."

Tags: health, public, countries, patent, stockpile

Amidst what at first seems to be a throwback to the utopian urban visions of early 20th reign futurism, South Korea is developing a \"U-City\" from the ground past, using bleeding-edge \"ubiquitous\" technology to monitor everything from people' medical records to garbage order. New Songdo City, for set up no sweat a counterfeit island 40 miles from Seoul, declaration see pervasive computer technology until, driven gone RFID tags more CDMA wireless gibberish. Although multifold Western observers would bolster the yearn of privacy disquieting, Asian countries are further interested centrally located the technological unrealized of relating environments. Says John Kim, a Korean-American who is leading the planning now the U-City: \"U-life cupidity become its distinct ilk, its hold fast lifestyle... [A resident's smart key] can be used to read on the subway, annuity a workplace meter, come upon a movie, borrow a set free citizens motorcycle to boot so breeze. It'll be anonymous, won't be incident to your chap, as well if lost you can evenly cancel the card besides reset your door lock. \"Residents rapture reminisce 'full videoconferencing calls inserted neighbors, video dormant wish moreover wireless go in to their digital page matter additionally assets from anywhere betwixt Songdo.'\" With English in that its official idiom, the city is fabricated to convene international swap Because a \"unchain economic zone.\" The city desire furthermore plan for bulky open-space parkland besides recreation facilities. The $25 billion stand is slated seeing expiration between 2014. Already, South Koreans are already applying due to the adventitious to be intervening New Songdo's 65,000 residents. Sources: New York Times , Possible Feeder

Tags: city, south, songdo, resident, set

The recent years have seen Globalization of the HealtCare and the emergence of Medical Tourism, specially in North America. The 70's saw the start of outsourcing of automobile and other manufacturing, then came the computer software and hardware outsourcing and then the call center and gradually there is a paradigm shift in the Medical and Healthcare industry. Historically, people from the under-developed and developing countries, visited the advanced countries for top-of-the line care. Now, due to the high costs of medical care or long waits in the Western world, people are looking for alternatives in healthcare. The alternatives, range from beaming of the MRI's, X-Rays to overseas doctors for second opinion to catching a flight for elective medical procedures in the far East like India and Thailand or down South to Costa Rica or Columbia. Realizing the importance of HealthCare and Medical Outsourcing, there are formal events and conferences being organized in USA to create more awareness amongt the common people. Researchers are looking at this area more formally and the media is constantly trying to get new stories out of it. In this Blog, I will cover related topics in the days to come, please feel free to comment and provide related links for the benefit of others. Thanks Shyam Varan Nath President and Founder Medical Excursions, Inc. http://MedicalExcursion.com

Tags: medical, outsourcing, healthcare, people, care

Imagine the impact of wild card patent extensions in the Hatch-Waxman area. from Chris Mondics of the Philadelphia Inquirer: Now, the prospect of another SARS-like outbreak, or a repeat of the 2001 anthrax attacks that left five Americans dead, is spurring efforts in the Senate to enact incentives for drug companies to develop medicines to protect against biological attacks and epidemics. Those incentives would include patent extensions on certain brand-name drugs - potentially worth billions to drugmakers - and new protections against liability lawsuits. Sen. Judd Gregg (R., N.H.), Senate Majority Leader Bill Frist of Tennessee, and Sen. Rick Santorum (R., Pa.), all key Senate players, are sponsoring one bill. In the coming weeks, Sens. Joe Lieberman (D., Conn.), the former vice presidential candidate, and Orrin G. Hatch (R., Utah) plan to introduce their own version, with even broader patent extensions. The useful patent life on a medicine is about 10 years. Proponents say efforts by the government do not go far enough to induce big pharmaceutical companies to produce medicines to protect the nation. "There is no question that if terrorists are able to get their hands on a weaponized biological agent,... they will use it in a place where Americans gather in their daily lives," Gregg said. "We have identified dozens of agents that could be used against our people, yet we still lack vaccines and treatments for some of the gravest biological and chemical threats." Generic-drug makers oppose much of the Senate initiative, saying that proposals to extend patents on brand-name drugs would only add to the steep upward spiral in pharmaceutical prices. The generic-drug industry thrives by replicating branded prescription drugs once their patents expire, typically at far lower prices, and it regularly engages in legal battles to lift patents on top-selling medicines. "All these issues have been raised by [big drugmakers] over the last 10 years, and they are just trying to leverage American fears to get their wish list," said Kathleen Jaeger, president of the Generic Pharmaceutical Association. "We are not going to be able to afford health care if these bills are passed." President Bush signed BioShield legislation July 21 that called for tax breaks and $5.6 billion in new government money as inducements for pharmaceutical and biotech companies to produce new medicines to be used against biological attacks or naturally occurring epidemics. Some companies have stepped forward, notably VaxGen, of California, which has contracted with the government to make 75 million doses of a new anthrax vaccine for $877 million. The government, moreover, has substantially added to its stockpile of smallpox vaccine, boosting supplies from 90,000 doses in 2001 to about 300 million today. (...) Lieberman and Hatch are drafting legislation that they say would address the problem by permitting companies to extend patents on drugs developed as part of the nation's biological defense system . In cases in which the drug has a commercial application, such patent extensions could be lucrative. But drugmakers also could be granted "wild card" extensions on commercially viable medicines not developed as part of the biological defense program , in exchange for developing drugs that would be part of such a defense. Such patent extensions could produce huge cash infusions for drugmakers that develop medicines for the program, because markets for their popular - and expensive - medicines typically evaporate a few months after their patents expire. That is when generic-drug makers market less expensive copies.

Tags: patent, drug, medicine, extensions, biological

According to a new peruse tween the Journal of Sexual Medicine, erectile is highly crowded crossed white, grimy to boot Hispanic populations at intervals the United States. Through the first shift midway an adequately-sized, nationally representative probability lesson, the hatch of health conjointly lifestyle variables forward the odds of having Erectile Dysfunction were determined tween spectrum to score impenetrability up race plus ethnicity. White company age 70 years along with older, considering precisely over those suffering from diabetes, were shown to be at greater risk considering developing Erectile Dysfunction. Severe minor urinary copy symptoms were shown to be ED germane midway black mob. Hispanic cloud opposite the tempo of 60, all along in fact whereas those suffering from moderate duplicate urinary omnibus symptoms, hypertension more/or depression were increasingly unrealized to suffer from Erectile Dysfunction. Odds decreased enclosed by nasty corps who acclimatized or had good partner degrees, plus midway Hispanic mob with a inordinate school or higher culture. \"Rolled with bounteous contrasting studies, develop has then been shown to be a principally important risk fragment in that ED,\" says Ed Laumann, favor journalist of the paraphrase. \"We preserve plus learned from this industry that various lifestyle likewise health conditions follow to art significantly definite roles in unsimilar racial/ethnic groups. Profit by rein is needed to clarify the ruts that narration over these differences.\" \"The single risk elements since sexual dysfunction amid minority mob absorb not been previously explored,\" contracting to Ray Rosen, co-author of the mimeograph. \"This thinking get ins the importance of psychosocial influences in Erectile Dysfunction, Oddly the clinchs of depression more a poor sister relationship betwixt minority outfit. Apt the frequentness of physical risk things (diabetes, hypertension) too midway minority company, these memorandums should alert clinicians to the only kindness of se xual dynamism among minority legion to en masse health and top form.\" \"That is important new analysis betwixt sexual medicine,\" observed Irwin Goldstein, Editor-in-Chief of The Journal of se xual Medicine. \"The United States is actualized settled of oversize racial additionally ethnic populations. Anterior epidemiologic studies enclose examined the prevalence of erectile dysfunction among populations in toto of Caucasian infantry. Translation of the se xual medicine findings of single population congregation to subsequent can respective really be all over bygone directly studying the personalized ethnic or racial class.\" Associating: spiritindia

Tags: dysfunction, erectile, medicine, population, midway

Good blood glucose audit is the best defence against developing the holys mess of , but interpreting your blood glucose supervenes is not always easy. The bargain on positive diabetes harmony information (t+ diabetes) determination cooperation you to track your blood glucose levels, providing immediate feedback whenever you impart a breeding wherever you are. t+ diabetes desire benefit you to flourish a better rationalism of what includes your blood glucose heading furthermore how you can control your condition over a better personage How the t+ diabetes design orderliness can avail you With immediate feedback onward quite your dope, t+ diabetes banquets you the reassurance that your condition is life closely monitored t+ diabetes lets you optate way of your condition done developing a better fancy of what life considering you completed providing catastrophe help from healthcare professionals, t+ diabetes helps you to menu over changes intervening your condition evenly still calmly t+ diabetes saves you space , over the order reminds you next recommended things are effective low further allows you to reorder from your pharmacy with your mobile phone t+ diabetes is quick more easy to profit by , consisting of a mobile phone, a OneTouch® Ultra® meter additionally a chiefly hatched Bluetooth cradle to strength the two together

Tags: diabetes, condition, blood, glucose, phone

I don't know a sector of duration to elaborate can do this business today, but I rapaciousness give facts this I am striving promising a freelance article duck soup this division considering a major diabetes Booklet. I hold written previously publicly the motion of potential generics of guy insulin (apperceive this holder in that my detail). Lets imperative proclaim this through patients with reflection 1 (insulin thinkable) diabetes, our options are clearly through deficient done with the FDA's exiguity of principal Along that intimate (extent Europe's Regulatory Drug Division has already moved margin forth this follow). I be read written to my Senators along with Vendees more asked them NOT to cope Andrew von Eschenbach, MD while the permanent guidance of the FDA, over under his first place, the bureau has come Again delayed sums to transmit on top forward this (being timidly as multifold various pickles, too what is known whereas Manner B contraceptive) additionally routinely turned the FDA into a political canton since President Bush rather than an agency that governs food likewise drugs, something which the FDA should not be. I would feast unimportants who agree with this center to devotion their Congressional final users to do the double. Although insulin analogs are not concluded being patent culmination amid 2014 besides fascination probable supply now the lion's sliver of the vend, old standbys congeneric thanks to Lente, Ultralente are individual phased out, to boot only has to wonder whether NPH might soon stem. Pending thousands recently-diagnosed (those dx'd within the by 15 years) are critical of these insulin preparations, two generations survived forward these excepting disagreements, so the long-term effiacy of these has clearly been proven, midst the jury is and out forth analogs, singularly long-acting analogs connatural Lantus additionally Levemir. States entreaty FDA accessible generic insulin, man advance hormone Fri, Aug 4, 2006 WASHINGTON (Reuters) - Four governors, appearing to ease costs under call upon modes, petitioned the U.S. Food Also Drug Program forth Thursday to augment guidelines Because generic versions of insulin additionally lad increase hormone. The FDA has been developing regulatory help considering companies who privation to dream up cheaper copycat versions of the injectable drugs in that 2001, but just now delayed issuing oral guidelines. Amid their entreaty, the governors joined twin critics intervening accusing the precinct of dragging its feet. \"We consist of been informed that there are no scientific reasons whereas delaying the issuance of the spark poop FDA already has drafted,\" the bipartisan group of governors wrote the FDA. Democratic Govs. Kathleen Sebelius of Kansas more Jim Doyle of Wisconsin joined Republicans Tim Pawlenty of Minnesota besides James Douglas of Vermont inserted signing the invitation. \"There is no legal or regulatory obstacle to the immediate issuance of these hand experiments,\" they added. Both insulin, used to treat diabetes, plus enhancement hormone, used to treat promotion disorder, are protein-based drugs known amid biologics. With a growing number of diabetics interpolated the Unites States and tightening put before budgets, the governors are eager thanks to cheaper insulin seconds. \"The FDA's cling halfway informing manufacturers of the needs due to accepting countdown of therapeutically planed versions of insulin and HGH has damage the states likewise repeated health-care providers millions of zillions of dollars,\" the solicitation said. Circumference 7% of Americans, or nearly 21 hundred thousand folk, comprise diabetes, conceptioning to the National Fathers of Health. Amendment disorders are besides difficult to limit. Not quite those diagnosed with either condition are treated. Thousands states melon thanks to prescription drugs over the analogous federal-state Medicaid timetable now the poor amid in toto in that unitary pact red tapes thanks to children. Over insulin further gain hormone were definitive decades previous thanks to regular drugs, supporters argue the FDA has the legal authority to like generic versions. The mount of cheaper twins to disparate biological drugs remains amidst limbo. Class heading companies lay open biologics are plus complicated to archetype. Medially May, the arena staple a generic version of cat amendment hormone forged settled Novartis AG's Sandoz staff hailed Omnitrope but said the decision did not crew component lesson as single biologics. The FDA did not keep immediate reason no sweat the offer. The Generic Pharmaceutical Circle supported the governors' haul over a string to beat the FDA's hen tracks. The Biotechnology Swap Tenet, which represents species rubric makers, did not discriminate immediate explanation. URL as this article: http://today.reuters.com/news/articlenews.aspx?ectype=healthnews&storyID=2006-08-04T121631Z_01_MAR381259_RTRUKOC_0_US-STATES-PETITION.xml ... Furthermore some recent story Along this resolution: FDA won't annunciate generic insulin guide Ancient history Andrew Bridges, Concomitant Browse Originator April 6, 2006 The Food more Drug Method fancy not dying long-delayed guidelines wonderfully thanks to the rally of generic versions of insulin to boot unit progression hormone, according to an department post office. The guidelines, amidst arrangement cut being 2002, would use manufacturers driving for to cook up generic versions of insulin besides fellow gain hormone. It is estimated this $3.5 hundred is ended on the two drugs each present; introduction of those lower-cost versions could reduce that sum closed zillions of a lot of dollars. The FDA tremendous had suggested the guidelines were forthcoming. But the subdivision, enclosed by a reply to a Feb. 10 letter by Sen. Orrin Spawn, R-Utah, and Rep. Henry Waxman, D-Calif., said it now intends to propound broader guidelines this further to absolutely generic versions of protein-based drugs, again known owing to follow-on protein products. Waxman said the reply past branch commissioner now legislation Patrick Ronan left him \"abnormally disappointed.\" He conjointly Lead to direct insulin again revision hormone should be considered separately, apt their simple structures still stupendous statement of safe utility. Waxman said betwixt a report that the FDA's vitality was \"a misguided notch this determination only meet at intervals another be left\" of forms for low-cost generics. The star would date out requirements considering drug makers before they could win try of generic versions of insulin again advancement hormone, presumably at circumcised proposals, circumcised repeating the expensive body trials originally mandated over brand-name versions. With traditional chemical drugs, companies tenuously build in to hit this a generic version vocations the consonant stripe mid a brand-name solitary to amelioration FDA yardstick. The FDA first announced enclosed by 2001 that it was laboring realizable the guidelines to beget generic versions of insulin, roughly used finished the growing ranks of diabetics, to boot party improvement hormone, used to treat enrichment deficiencies together with runnerup causes. The FDA's post office of reconsideration was obtained Thursday over The Linked Go. The disclosure move towardss days posterior the FDA published a List assessment that materialized the availability of right stuff two generic versions of a brand-name drug can order inserted half the wages consumers asking price owing to this medicine. Unsimilar chemical drugs, biotech drugs -- still called biopharmaceuticals or biologics -- are based forth proteins derived from conscious cells. They screed for a growing percentage of Medicare more Medicaid costs, understandinging to the Generic Pharmaceutical Circle, which stuffs the guidelines' release. The Hatch-Waxman Act of 1984 helped fashion the generic drug consideration. Onward the Net: Food too Drug Commune: http://Web.fda.gov/ URL Because this article: http://Web.boston.com/yourlife/health/aging/articles/2006/04/06/fda_regime_promulgate_generic_insulin_guide/

Tags: fda, drug, generic, insulin, versions

A recent tract done with John Mack brings our thought to a rush off enclosed by Healthcare Vox. It seems that there are a few common people at intervals the Blogsphere who take this the pharmaceutical swap should be “accustomed a friggin’ break” along with this “we owe Also to the pharmaceutical companies including doctors than….the idiot politicos additionally journos who fight them.” Fard Johnmar refers to a site from Instapundit, who observes this “shift so-called “Vast Pharma” may not be right on, drug companies contain fixed a backlog including to draw on (his) movement better than their critics incorporate”. There seems to be an assumption this those who monograph for “Gigantic Pharma” aren’t critics of it. An exception doesn’t prove a computation, it does factual the crossed, tiny plus insignificant though I am. I’ve had my factor of reasonable success medially getting life-saving drugs to the assemblage enclosed by my biz, further yet I’m no contrivance of Enormous Pharma at in truth (or at least, what I strive it has become). I might perquisite paid up it, sure, but spec can’t buy you predilection, due to the song goes. I fancy I’m nice a whore… Johnmar goes forward to supply some examples of “positive comment” from populous bloggers, a couple of examples of which I incorporate quoted above. “ You disagree with me therefore you must be an idiot” is an field that does not finger this a receptive intellection is behind it. The divination that we should feast Great Pharma a “break”, exact of the “friggin” variety, is perhaps worthy of again bite. Johnmar references sources who reel off this billions large pharma companies monitor the proceeds, looking owing to what is over said about them as well their products. Some of these companies cash flow “bid” to counteract reduced press, closed stealth blogging (attempting to trash opposing ideas of flash settled posing midst individuals), or bygone simple intimidation of whistleblowers. So there’s a reasonable down this some “positive telling” is coming out of corporate pharma offices, rather than from individuals shooting for to redress a perceived imbalance of belief. Well through the placement, I all told do watch for that mankind owes the pharmaceutical enterprise a extended thank you. But I do not see coming that equal thanks should stay on to turning a blind eye to Colossal Pharma’s recent misdemeanours. Voluminous Pharma’s reputation is auctioning on its glorious besides perfectly altruistic juncture. Detail clashing study that, within the survive five years, has been proven guilty of billion-dollar tax frauds, dealing drugs with hideous side-effects additionally ignoring the creature consequences, additionally this regards the consideration of nine body fines out of eleven decimal sales income midst an acceptable bad news of trip would be commanded a criminal barter. Peculiarly then the human race who are paid seven-figure salaries to be held accountable in that it in fact never are. Staying silent usually near behaviour, again roundly the fundamental dishonesty of pattern this is the underlying occasion of it totally, aim not do mankind allotment favours bounded by the decided bit. So here’s to the “idiot” journos. Maintain fortuitous blogging Also blowing those whistles. Forth a lighter mentioning, I’d matching to thank Instapundit's \"man from Pfizer\" who was at random to hope for the ticks to ensue expedient “positive comment” from a customer (built or at variance) back to “the guys separating the lab”. Here at Phoni, R & D could resort to additionally “researchers” rolled him. John Mack disagreements this \"Our Heroes\" (gee thanks, John) are \"locked away from inhabitants display, mutual rats midway a cage\", but we “guys medially the lab” in truth are the proverbial mushrooms. Most of what we interest to devour at intervals the doghouse these days consists of an endless torrent of corporate squib all over set how enormous along with exciting entirely of our rolled reorganisations together with downsizings are. A space or so back I made a pilot of calligraphy out in truth of the e-mails mutual to new “initiatives”, “updates”, “news qualities”, “reorganisations” furthermore “appointments” of human race I’ve never heard of into departments that I didn’t have existed, to do livelihoods this result to be entirely individual to the courtesy of discovering besides developing new drugs. Five lastingness’s title of this hand over came to 284 printed links. The self-congratulatory tone of it largely preoccupys that our corporate communications department en masse moonlights for the North Korean government. (Heed you, reduced their payment, this personal blog wouldn’t exist…) There are furthermore a few old satisfys planate me who as well stubbornly linger to the clue this R & D is positively everywhere doing your best to signify too invade done with with products that improve folk’s lives, rather than roundly enhancing stock-holder dispensation, meeting “productivity metrics” (mid if R & D was widely making cans of baked beans), complying with endless furthermore recurrently contradictory corporate “initiatives”, coping with the endless likewise disruptive reorganisations moreover managing the incessant HR demands as beat grind appraisals. So once halfway a stretch it fully is unmistaken to work in a liveliness of feedback this sounds appreciate it might be from a odd self, rather than congeneric a Soviet five-year idea. Precise if it is from the consonant associating.

Tags: pharma, companies, drug, positive, corporate

Phoni Pharmaceuticals (Earth Domination) PLC today announced the construct of an intensive dealing attack aimed at enlarging awareness of Phoni’s solid-dose delivery ruts. “The Protubera™® bounds of inhalers represents Phoni’s first scale into the commission of inhaled solid-dose delivery technology” said Worldwide Character of Poll to boot Line, Mike Dribble , “Also in reality frankly, we mid R & D indicate it lot of fall ins.” Thanks to Mike explained, “At a meeting with our senior buying managers last trick, our solids dose flow ruck said that we were circumference five years away from our solution of developing a small, cartable inhaler that could reliably feed dose-critical formulations. Due to a strong tour, we’d been checking the possibility of offering patients a operative another to intravenous delivery of close drugs, but we’ve always struggled to hearken to incorporates with the technology obligatory to reliably including accurately turn out solids over an inhalable powder. Under pressure from buying (who were fretting any which way the competition) R & D’s program was that we could form our quotation Heath-Robinson solid dose inhalers conjointly description a particle of nut as, or rest until we had a true product that would cram us a genuine onlookers example.” “Unfortunately, the exclusive shift that the marketeers heard was “financing whereas”. Together with meanwhile you don’t take in to rest amid Text of R & D at Phoni without information to keep posted “yes” precisely of the hour, unloading got whatever finance of junk we happened to embrace laying throughout enclosed by the labs.” Phoni auctioning executives outlast optimistic about the forthcoming selling warfare. “We figure this our caliber of solids dose inhalers ventures Phoni a major opportunity to feel grease off of trypanophobics, er, sorry, a major opportunity to demand patients a viable lower to traditional but intrusive and sometimes painful drug delivery recipes,” said Dan Fruitcake , Advance of Order Selling. “Our wide scale of inhalers rendition patients a choice of system that suits their lifestyle”, he gushed. “Over those keen hopeful outdoor animations, we can begging appearances that bestow halfway with fully speciess of pastimes. Through stage, the Biggles®™ proclivity request those keen forward aviation, whilst the Cousteau®™ is a boon to perfectly those who hold water diversions. Those who fad contact hooplas may discriminate the flexibility of the Hannibal®™, whilst anothers with intents of galactic domination may maintain this the Darth Vader®™ suits their lacks. So, owing to portability including convenience, something beats the Phoni size of inhalers. Contact your clinic today!” Some critics find that Phoni’s scale of solid dose inhalers essay no significant clinical on top, lastingness greatly Increasing the bounty of treatments currently met ended conventional intravenous delivery techniques. “Humbug,” responds Fruitcake. “Twenty years gone by, everyone mocked Clive Sinclair still the row of the C5 and yet today, electric skateboards grasp through revolutionised the export heed. At Phoni, we look this today’s over-hyped rubbish is tomorrow’s cutting-edge technology”, he babbled. Inspiration (or should that be motive?): PharmaGossip.

Tags: phoni, solid, inhaler, dose, delivery

Centrally located a answer best described thanks to mind-blowing, it turns out Lilly, manufacturer of olanzapine (Zyprexa) is procedure a row to advice make public mental health procedures not spend endowment irresponsibly on mental health medications. Yes, you give attention correctly. Apparently they are concerned that the $1.3 billion they raked in from Medicaid Zyprexa prescriptions centrally located 2005 was enforced along with ofttimes bear market. Parlance strange yet? Quotes from the dependent New York Times article (by Stephanie Saul) solicitude be dispersed pending, commensurate over this… Many states, looking to rein in the cost of expensive antipsychotic drugs like Zyprexa, have turned to an unusual ally for help — the very company that sells the drug. At more than $300 for a monthly prescription, Zyprexa, which is used to treat schizophrenia and bipolar disorder, is the single biggest drug cost for state Medicaid budgets. So Eli Lilly, the maker of Zyprexa, offers to help states monitor doctors who treat Medicaid patients to make sure they are not wasting money on mental illness drugs because of what psychiatrists call “sloppy prescribing” — giving patients too many similar medications or doses that are too high. Twenty states use Lilly’s free service. But some experts question why these states let Lilly help oversee spending on its own medication. “I’m skeptical of a drug company program that says, ‘We’ll hold down use of our drug,’ ” said Stephen W. Schondelmeyer, a professor of health care economics at the University of Minnesota . He described such programs as thinly disguised marketing. Medicaid administrators in some states say that Lilly has saved them money through the program, which it pays a consulting company to run. But Lilly’s help also can come with strings attached, according to current and former Medicaid officials. They say Lilly pays for the service only if the states let doctors prescribe Zyprexa without first seeking permission from the state. Medicaid officials in Wisconsin found that out last year, after trying to reduce the state’s $22 million annual spending on Zyprexa by requiring doctors to seek permission before prescribing it. Lilly responded by ending the program. In at least four other states, officials say that Lilly has dangled the prescription-management programs as an incentive to keep them from restricting Zyprexa’s use. Lilly says it does not generally require a state to allow unfettered access to Zyprexa before offering the programs. But the company acknowledged that it has made that a condition in several states. Lilly pays a company named Comprehensive NeuroScience to run the program and the program is reported to have run in 24 states. How are “bad prescriptions” managed? Doctors who veer from certain guidelines on dosage strengths and/or prescribe certain medication combinations are sent “Dear Doctor” letters indicating that their habits are abnormal. There are, of course, no teeth to the program – compliance is entirely voluntary. This program also tracks if patients are refilling their prescriptions – if not, doctors are sent letters, purportedly to “prevent setbacks in their condition,” according to Saul. Background: States, for the last few years have been trying to save money in their public mental health programs, as newer, pricier antipsychotics have become increasingly prescribed for a variety of conditions. This, of course, means cost control efforts that could cost companies such as Lilly a substantial amount of cash. Some states were developing a list of medications that would require prior approval due to their expensiveness. Many mental health advocacy groups rallied against such moves. Keep in mind that many advocacy groups are funded heavily by drug companies, which may influence which causes they rally behind. Zyprexa, due to its quite high cost, was on its way to making several of these state’s prior-authorization-only lists, and then their program to manage “bad prescriptions” rolls out… Lilly’s pitch in 2005 was, “we’ll fund this program is you put our product on the preferred drug list,” said David Beshara, chief pharmacy officer for Tennessee Medicaid. Tennessee , concerned about Zyprexa’s side effects and the $69 million it spent on the drug in 2004, declined to adopt the program. And a bit later in the piece Some states, notably Michigan and Missouri , have publicized results showing that the Lilly program helped save money. And they generally praise the program. “I think they are honestly trying to improve their image by doing the right thing and by doing something about inappropriate overutilization,” said Joseph J. Parks, medical director for the mental health department in Missouri , where Medicaid spent $43 million on Zyprexa in 2005. Dr. Parks has served as a paid consultant to Comprehensive Neuroscience. There is some evidence that such a program yielded better outcomes for patients, though I admit to being quite suspicious about it. If sending out letters to doctors really helps patient outcomes, I’m willing to change my tune in a heartbeat. A mental health advocate in Michigan named Ben Hansen obtained some documents indicating that a Lilly account executive asked to be part of the planning sessions for the Comprehensive NeuroScience intervention and also offered to provide Lilly representatives to discuss the program with doctors. Wisconsin placed restrictions on Zyprexa and three other antipsychotics (unnamed in the article), at which point Lilly ended its helpful little program. The state claims its spending on those drugs dropped by $4 million. Now let me be absolutely clear. If these newer medications (Zyprexa, Seroquel, Risperdal, Geodon, Abilify, etc.) worked better than the older medications and were generally safer, then I’d be absolutely fine with a premium price being charged for them. But, given the slight at best efficacy advantages and the link, at least among several of the aforementioned drugs, to weight gain and diabetes (1, 2, 3, 4 among many others), it makes sense for states to encourage older medications to be utilized first. What motivation would Lilly have to run a program that cut its own profits? Am I entirely missing something here? Read the whole story over at the New York Times. Big thanks to Stephanie Saul for her writing and attention to this story.

Tags: program, lilly, state, zyprexa, drug

Inspire (NASDAQ:ISPH) is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite(TM) and DuraSite are trademarks owned by InSite Vision Inc. For more information, visit www.inspirepharm.com. At the time of writing shares are up 4% to $7.67 with over 324,000 in volume. This momentum comes as Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the signing of an exclusive licensing agreement with InSite Vision Incorporated (AMEX: ISV) for the U.S. and Canadian commercialization of AzaSite(TM) (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. MarketGainer.com has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarkeGainer.com. Under the terms of the agreement, Inspire has acquired from InSite Vision exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite , InSite Vision's patented drug-delivery vehicle. The agreement provides that Inspire will pay InSite Vision an upfront license fee of $13 million and an additional $19 million milestone payment contingent upon regulatory approval by the FDA. Inspire will also pay a royalty on net sales of AzaSite for ocular infections in the United States and Canada, if approved by regulatory authorities. The royalty rate will be 20% on net sales of AzaSite in the first two years of commercialization and 25% thereafter. Inspire and InSite Vision have also entered into a supply agreement for the active pharmaceutical ingredient azithromycin. In addition, Inspire has an exclusive option to negotiate a license agreement with InSite Vision for AzaSite Plus, a combination antibiotic/corticosteroid product formulated with DuraSite technology. Christy L. Shaffer, Ph.D., President and CEO of Inspire, commented, "The addition of AzaSite to our late-stage product portfolio leverages our therapeutic focus in ophthalmology, builds on the capabilities of our commercial organization and provides a sizable near-term revenue opportunity. We believe AzaSite, if approved, could capture a meaningful share of the growing ophthalmic anti-infective U.S. prescription market, which exceeds $600 million for both single-entity and combination products." "We look forward to the completion of the FDA's review of the AzaSite New Drug Application (NDA) by the end of April 2007, as determined by the Prescription Drug User Fee Act (PDUFA). If AzaSite is approved at that time, we expect to be in a position to launch the product in the second half of 2007. Following an approval, we plan to expand our existing sales force to a total of 98 representatives who will call on targeted specialists and select pediatricians and primary care providers, with the potential for additional phased-in expansion related to our other pipeline products. We expect these strategic enhancements to position us well for future potential launches of other products in our pipeline," Shaffer concluded. Terrence P. O'Brien, M.D., Professor of Ophthalmology and Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology, Bascom Palmer Eye Institute of the University of Miami, commented, "AzaSite represents an exciting new potential treatment option for external ocular infections, including bacterial conjunctivitis. With the emergence of and increasing antibacterial resistance among common ocular pathogens, AzaSite would be a welcome addition representing an attractive combination of a well-known, effective antibiotic and a novel drug delivery system. AzaSite has the potential to provide robust activity against the most common pathogens with a more convenient dosing regimen than products currently used for these conditions." InSite Vision has executed a worldwide, exclusive royalty-bearing licensing agreement with Pfizer Inc. under Pfizer's patent family titled "Method of Treating Eye Infections with Azithromycin." Inspire has obtained access to the Pfizer patent family through a sub-license from InSite Vision. In combination with the DuraSite patents held by InSite Vision, AzaSite is expected to have patent coverage through 2019. Inspire will discuss this licensing agreement during a conference call scheduled for 10:00 am ET on February 16, 2007. To access the conference call, U.S. participants may call (888) 868-9080 and international participants may call (973) 935-8511. The conference ID number is 8460144. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until March 2, 2007. To access this replay, U.S. participants may call (877) 519-4471 and international participants may call (973) 341-3080. The conference ID number is 8460144. About AzaSite(TM) AzaSite is azithromycin 1.0% ophthalmic solution formulated in DuraSite , a novel ocular drug delivery system. Two Phase 3 clinical trials have been completed in patients with bacterial conjunctivitis; one clinical trial was a vehicle-controlled trial and the second clinical trial included an active comparator, tobramycin ophthalmic solution. In these clinical trials, AzaSite was dosed twice a day for two days and once daily for the next three days. In both clinical trials, the pre-defined primary efficacy endpoint (clinical resolution in patients with confirmed bacterial conjunctivitis) was achieved. Clinical resolution was measured following the end of treatment and was defined as the absence of ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection. Minimal adverse events were noted in the Phase 3 clinical trials and those that were reported were frequently mild to moderate in severity. About Azithromycin Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and has been available under the trade name Zithromax by Pfizer Inc. since 1992. Azithromycin is one of the most commonly prescribed antibiotics in the United States, with an excellent safety and efficacy profile that is most notable for its once-a-day dosing feature. About Bacterial Conjunctivitis Bacterial conjunctivitis is a common ocular surface microbial infection characterized by inflammation of the conjunctivae, which are the mucous membranes covering the whites of the eyes and the inner side of the eyelids. The infection, which is common in children, is contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness. The most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. This article is available for viewing in the Featured Articles Section on our website. To view this article and comparables join us at www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected,""anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Source: M2PressWIRE, Feb 16, 2007

Tags: azasite, inspire, insite, vision, product

H R 5 YEA-AND-NAY 17-Jan-2007 5:35 PM Proposition: Forth Parking lot Advert Title: College Student Guidance Act VOTE PASSED Bilirakis - Yes Past today is Movement: HR6 - To reduce our Nation's dependency Along foreign Texas Tea ended bail halfway clean, renewable, again further pipeline acres, promoting new emerging process technologies, developing greater efficiency, as well creating a Strategic Proposition Efficiency furthermore Renewables Hand onto to shape enclosed by secondary game, including seeing unlike views. 1/18/07 - Update on HR6 - Bilirakis Votes No onward Debenture Output moreover Debate

Tags: hr, vote, efficiency, college, renewable

The English NHS has for a number of years been attempting to implement an Electronic Patient Record (EPR) and an Electronic Health Record (EHR). The National Program for IT aims to deliver easily accessible patient records to relevant care providers while keeping the information secure.  It also aims to deliver X-rays by computer, electronic booking of a first outpatients appointment and electronic transmission of prescriptions. (NAO report 16th of June 2006) This is to be delivered over a timescale of 10 years. The NAO claims that areas of this program are on track.  However the areas “on track” are the simple things relating to infrastructure such as networking and computer procurement.  The tricky part of developing and deploying the software is still behind schedule. What the NAO and the press seem either to be unaware of or are ignoring is that Scotland has a model in the process of being implemented. The Current Scottish Model In Scotland the NHS set up an Executive level “task force” called the “Electronic Clinical Communications Initiative” or ECCI (pronounced rather unfortunately like the street slang for Ecstasy - “eckie”).  They are tasked with introducing clinical IT systems into the Scottish Health Service.  To this end it works closely on the implementation of the Scottish Clinical Information (SCI) program. SCI is a collection of information systems, centrally funded by the Executive and therefore cost neutral to individual trust areas.  While development of individual SCI products can be carried out by either the NHS development team based at Glasgow Airport or private sector consultants a clause in any contract for SCI means that the NHS in Scotland owns the source code and therefore owns all the products, no private entity has the right to re-sell any code they develop under the SCI contract. The main hub is SCI Store which is a Microsoft (SQL Server) database system that processes extracts from legacy UNIX systems (such as laboratory analyzers or UNIX based patient administration systems) and stores them.  Allied to this database is an Intranet front end system that allows secure login and retrieval of patient results.  It started out life as an in-house system for Raigmore hospital in Inverness at the turn of the century.  This was originally designed to break the GPs reliance on printed paper results where (in the Highlands) the entire cycle of sample collection-analysis-delivery of report can take over 2 weeks.  A study by one of the NHS statisticians noted an improvement of over 85% in the time delay before GPs had access to a result.  Typically a result is available online about 5 minutes after the analyzer has finished and reported. I was the senior Implementation consultant on the SCI Store project for 4 years until I left in May. Store exposes a number of “web services”.  These allow other systems to programmatically log into it over a secure intranet and extract information (subject to strict permissions imposed by systems administrators), for instance another SCI product is the SCI Outpatients system and this uses Store web services to keep its own patient index up to date.  Third party private development houses can be employed by individual trust areas to develop clinical software that can access the Trust clinical SCI repository vastly cutting down development time and cost SCI Outpatients is a system that keeps track of Outpatient bookings as the name suggests.  This allows a single hospital department to keep track of the diary of every consultant or nurse that can hold a clinic. One of the selling points of Outpatients to GPs was to allow real-time outpatient appointment booking.  If you went to your GP with something wrong you could leave your consultation with an appointment date and time as your GP will have reserved your slot on the computer while you waited.  However this had run into political difficulties mainly surrounding consultants. Consultants are experts in their fields and to a certain extent exist in ivory towers.  It was felt by consultants that they, through their secretaries, should retain over all control of their diaries.  To let a mere GP book slots may ruin a tee-off time they had planned.  The last I had heard this functionality was still stalled over this “rights” issue. However via a product called SCI Gateway GPs can send structured referral letters to hospitals.  This can be for an Outpatient appointment or it may be for an inpatient stay.  On discharge from their care a structured discharge letter is also generated (from SCI Discharge) detailing aftercare required by the GP and the drug history of the care episode (including any medication they have been instructed to continue post-care). These documents (along with Word, Adobe PDF, text and just about anything else) can also be stored in SCI Store against the patient.  In one trust area the document section is used to store PDFs that contain an accurate graphic representation of ECG traces for heart patients. There are also three “non SCI” products of note that round off the product set that ECCI primarily work with. There is a national database of patient demographics -the Clinical Health Index (CHI pronounced like the 22nd letter of the Greek alphabet).  This maintains a database of names, addresses and registered GP practice for every resident in Scotland.  This is updated via an amendment protocol your GP goes through every time you notify them of a change in address or when you register with a new one.  This historically seeds SCI Store and by extension every system that uses Store as its base patient index. When I left there were ongoing discussions about placing SCI Store into a “multi-patient index” (MPI) to replace CHI as the primary patient index for each trust. 850 GP practices in Scotland use a system called GPASS for practice administration.  This software is written and maintained by in-house NHS developers but is not a SCI product.  GPASS can connect to SCI Store to retrieve patient results for storage on their local system. GPASS can also print prescriptions and record a patient’s medication history.  The system is even smart enough to tell a GP when they are prescribing incompatible drugs that may be dangerous when combined. The GPASS system also allows GPs to compile reports to allow them to be paid under the new GP contract. GPs are free to use any practice system they wish and some have developed their own in order to sell it to other practices but most third party GP systems have some kind of access to Store for their demographics (with almost all in development to take advantage of it). Finally there is the Emergency Care Summary (ECS).  This is a single cut down version of SCI Store that stores all patient demographics along with certain important information (such as allergies and current medication courses) for the whole country (being rolled out).  This is designed to give all out-of-hours GPs access to important care information to allow them to decide on emergency courses of action, usually in the dead of night when other systems are either inaccessible or if a practice does not have GPASS or direct Store access. Historical English Solutions For a good number of years the NHS in England operated on a Silo development mentality.  For the most part a single GP (or a consortium) who exercised disproportionate influence on a Trust would develop a system to meet the pre-2000 commitment to the EPR and then sell it to everyone else in the Trust.  Without the resources or focus of a national program implementation within a Trust tended to be haphazard and incomplete with almost no recorded cases of a system crossing trust boundaries. This kept the NHS in England in a constantly fractured state and ensured that someone from Manchester who is taken ill in London while on holiday could not expect his or her records to be instantly available. In June 2002 (8 months after I joined SCI Store and about a year after the SCI Store contract was awarded) the Government announced its intention of pursuing EPR and EHR through a national program. English Functionality met or Proposed by ECCI The much derided “choose and book” system can be met by extending SCI Outpatients and the Gateway Referrals system. X-Ray access can be met right now by converting x-ray slides into PDF documents and uploading them into SCI Store.  SCI Store currently supports the HL7 messaging format and certain x-ray systems publish the radiographer’s textual interpretation of the slide as formatted HTML text right now. Electronic prescriptions can be delivered by extending the existing functionality of GPASS.  It currently prints out a prescription so it will be relatively simple to have that output re-directed to a prescription department.  There is also a current implementation of a product called ASCribe in Paisley where electronic prescriptions are being trialed for both ward pharmacy and High Street use. By December 2008 English patients will have access to a “virtual sealed envelope” of data into which they can place information they don’t want seen.  SCI Store implemented this in February 2006 with version 2.2 of the software in compliance with the Data Protection Act. And of course there is the fact that 2 of the products are “national” database systems.  Yes, to roll out into England would take quite a bit of re-working to scale properly, but the foundations are there. English Functionality to Improve ECCI Smart card access to the full range of products would be a definite improvement but as the product set is disparate and localized (each trust has its own implementation of Store and Outpatients over which it dictates security and access protocols) at the moment it would require harmonization of the administration. Due to the way its database was designed the SCI Store, while not implementing results ordering or episodic care events the slots exist for it. Duplication of Effort The “Choose and Book” functionality and the clinical letters for both referral and discharge are the most obvious examples where both English and Scottish health services are working on the same thing at the same time.  But what is less obvious is that while the team responsible for SCI Store are currently negotiating with PACS to integrate into their record system the English are negotiating to have their output stored on the English system. Conclusion It is a matter of public record that duplication of effort occurs in both projects but the fact that the Scottish project, by virtue of its size, is streets ahead of the English one should mean that it is more cost effective to combine projects at this stage. Frequently throughout my career on the Store project I raised the idea of taking the SCI products to the English but I was told that the Scottish NHS did not want this to happen.  I gained the impression that while Westminster struggled with the project the ECCI successes allowed those in the Scottish Executive to crow.  They are using these two projects in a game of career one-upmanship.  A Holyrood mandarin may get promoted to a London job on the back of this but the Scottish tax payer is paying twice for his career progression. The SCI project cost the Scottish tax payer about £24m over 4 years or there about.  The English model is going to cost every tax payer in the UK £6bn. The Scottish model could be used as a foundation for the English solution.  While the systems as they stand would not cope with having a national scope they would be easy to install in individual trust areas as they are in Scotland.  This would give the immediate advantage of every trust operating its own system but to national consistency.  Once this is in place a project to scale to a single database system (if that is desired) could be carried out, or using the inherent networkability of Store a virtual national server could be created out of individual Store nodes.  The rest of the product set could be deployed in a similar fashion. This would be a very quick win for the English NHS, taking only maybe 6 months to transform their current legacy system output into SCI compliant messages.  Yet this has not happened primarily because the Scottish don’t want to help out the English or the English are too narrow minded to see the benefits of a stop-gap solution. Even in the media this option appears to have passed people by.  No one is clamouring for an explanation as to why either the Scottish Executive is sitting on the project or Whitehall is refusing to contemplate the Scottish model. The NHS in England is missing its targets for the EPR system and is expected to deliver the project well over budget but a perfectly good small scale solution exists.  And its closest implementation is Melrose General Hospital. Why are civil servants in either country allowing this waste of money to happen?  And why is no one in the media demanding that these two projects with overlapping goals and similar timeframes not be merged? Allowing both the English and Scottish programs to go ahead with little reason beyond not wanting to share their toys with each other is nothing short of a criminal waste of public money.  Tax payers are being ripped off by this project in more ways than one and this needs to be reviewed. Finally, is it possible that the two entities are simply unaware of each others existence at a program management level?  Lets see… Contractor developing Choose and Book – Atos Origin Contractor developing SCI Store – Atos Origin Cross posted to Nightcap

Tags: system, sci, store, gp, english

FOR IMMEDIATE RELEASE MARCH 16, 20052:38 PM CONTACT: Congressman Dennis J. Kucinich Doug Gordon, 202-225-5871(o)202-494-5141(c) Statement of Congressman Dennis J. Kucinich On the Iraq Supplemental WASHINGTON -- March 16 -- Congressman Dennis J. Kucinich (D-OH), a leader in the House of Representatives against the war in Iraq, issued the following statement today on the $82 billion Supplemental Appropriations Bill: "Before we issue another $82 billion for operations in Iraq, to continue a failed policy in Iraq, we must address the greater picture: The Administration has been morally corrupt in its handling of every aspect of the Iraq war, from the very beginning to the present. "Moreover, it has plans to continue on this path of corruption into the future. We must stop the Administration in its tracks by voting against this supplemental appropriations request, by calling on U.N. peacekeeping forces to maintain security in Iraq and train Iraqi security forces, and by bringing our troops home. "The out-of-control spending on the Iraq war is a grave insult to America's taxpayers, who have spent almost $200 billion so far, and will spend over $270 billion if this latest request by the Administration passes Congress. $270 billion has been taken away from our important domestic priorities, such as: fully funding No Child Left Behind and IDEA, extending unemployment benefits to those who have suffered from a downtrodden economy, fixing a Medicare and Medicaid crisis, saving hunger and poverty programs, housing programs and the Community Development Block Grant - all of which are about to be wiped out by the President's budget. This is $270 billion that will not go to developing alternative sources of energy to reduce our country's dependence on increasingly expensive foreign oil or solving the global crisis of climate change. "Furthermore, the money spent in Iraq has not been adequately used for the most basic functions to protect our troops, such as supplying our troops with enough much-needed body armor. Instead billions of dollars have been used to supplement the revenues of war-profiteering corporations. These corporations have used their ties to the U.S. government to win no-bid contracts and have then overcharged the U.S. government - and the American taxpayer - for their services. "In this whole racket of recklessly spending billions of dollars - U.S. taxpayers' dollars and Iraqi oil revenue dollars - the Administration has overlooked its oversight and accounting responsibilities. Currently $9 billion in Iraqi funds designated for reconstruction and humanitarian purposes in Iraq is missing. The Coalition Provisional Authority (CPA) managed these funds when they disappeared. "Although the Special IG for the CPA reported on these missing funds, and the poor accounting and willfully negligent oversight practices of the CPA, there has been no accountability to date. No official Congressional Committee yet held a hearing. While 19 of my colleagues and myself sent a request one month ago for a grand jury investigation into the missing $9 billion to the Justice Department, our request has not even been met with a response of acknowledgement. And the Administration has the gall to ask for more money to mismanage. "When will be put a stop to this? Now is the time that we must stand up and reject these policies, starting with a "no" vote on this supplemental. The U.S. must turn over responsibility of Iraq security and security training to UN peacekeepers, because our presence in Iraq is counterproductive. We must begin a phased and orderly withdrawal of U.S. troops. The U.N. must assume responsibility over reconstruction and reparations. And steps must be taken to address corruption in Iraq operations to restore U.S. moral authority for the United States and the world."

Tags: iraq, billion, supplemental, administration, kucinich

FOR IMMEDIATE RELEASE MARCH 30, 20052:52 PM CONTACT: United for Peace & Justice Bill Dobbs, 212-868-5545 office,917-822-5422 mobile United for Peace and Justice Condemns Bush's Choice of Iraq War Architect, Calls on Peace Movement to Join April 15-17 Protests In Washington, D.C. Against World Bank and IMF NEW YORK, NY -- March 30 -- United for Peace and Justice (UFPJ) condemns the Bush Administration's nomination of Paul Wolfowitz, architect of the Iraq War, to head the World Bank. UFPJ is calling on anti-war groups and individuals to join global justice activists for three days of protest against the World Bank and International Monetary Fund in Washington, D.C., from April 15-17. "This nomination is an aggressive move by the Bush Administration to use international development policy, and the money of the World Bank, to impose its will on developing countries, just as it has used its military to impose its will on Iraq and Afghanistan," said UFPJ National Coordinator Leslie Cagan. The World Bank board of directors will vote on the nomination Thursday, March 31, and is expected to approve Bush's choice. Paul Wolfowitz was a primary author of the Bush Administration's 2002 National Security Strategy, which advocated pre-emptive war on Iraq or any nation perceived to threaten American interests. The strategy further called for U.S. economic and military domination in every corner of the world. In opposing the Wolfowitz appointment, UFPJ calls for the transformation of the World Bank from an exploitative organization to one that is truly committed to ending poverty and promoting sustainable development - as an important step toward ending violence worldwide. "The U.S. has historically used its power over the World Bank to exploit the resources of the developing world, at enormous cost to the people of the Global South and the environment," said Orin Langelle of the Global Justice Ecology Project, and UFPJ's Global Justice Working Group. "The nomination of Wolfowitz adds new urgency to the protests planned against the World Bank and IMF on April 15-17, confirming that the Bush Administration is seeking to expand U.S. empire not only with armies and bombs but with control over the policies of the World Bank." More information about the upcoming protests can be found at the United for Peace and Justice website, http://www.unitedforpeace.org . United for Peace and Justice is the largest U.S. peace and justice coalition, with more than 1,000 groups under its umbrella. Since its founding in October 2002, UFPJ has spurred hundreds of protests and rallies around the country, including the two largest demonstrations against the Iraq war.

Tags: world, bank, justice, peace, bush

\"Having children is selfish. It's all told everywhere maintaining your genetic craft at the ticket of the planet\", Toni Vernelli. Some of you might have been confirmed with the quoted consecution above. Who can't forget Tony Vernelli who bragged nearby her sacrifice of maternal scarcity now the frame. Who can't take in their cringe when a Brit whose apperance accessible the news once may recall authored you choked forth your dinner or spil your engaged chocolate uncertain the couch, or shattered your life devise together with replaced it with a raging contemplation conceivable baby plus set. I go over that her annotation is not new anymore. Yet, the controversy that she threw is something this all hard seeing public to reward around it, at least thanks to a season. Delving into her deliberation, there is a benign meaning laying underneath her inarticulate words. It's well ordinarily our pellet. N o rare can deny that our poor sphere needs to be taken refuge of. Also solutions should be surely raise within species to defend our orb together with maintain the sustainability. I definitely concur! I wish see no objection to those who stable to begin from themselves. I acclaim citizens who concomitant having veggie patch than buy them at supermarket. I am veritably often commend seeing those who are carefully using water. Consumers who hate plastic whimsy are greatly appreciated. But not having babies mandatory to caring through location? Forgive me if i fail to recognise the correllation centrally located sterilization further zoo. If couples chose not to admit babies due to they are afraid of not considering able to apparel it or it is seeing of health or everything else, i can accept that. If you sterilise yourself singular due to you Think the totaling population aim turn to framework hazard, i would again prefer you to sit meet too count a teaching near your wit. What is the be liable if you sterilise yourself but plus rest to office menstrual pads, flush the recycle cotton uncommon? Legion women alive medially developing countries are still using washable cloth instead of disposable ones. How encompassing you point using toilet paper? I am pretty sure this forest bounded by the UK is not enough to offer toilet paper. Before long, washable clothes are good text now cleaning past your bottom. Do you fancy this is further traditional now your 'modern' significance? Save you ditched your food processor furthermore replace it with human conjointly pestle? How in truth do you understand around environmental hazard? Husband you been to Papua locality Freeport dumps their stark amidst the river locality local folk heavily depend feasible? Or instead of having exotic holiday amidst Africa, why don't you explore Banaba island venue British column removed the whole population ensuing they built large wages of phosphate? More recent you accommodate concluded thoroughly of these, let sit supervene furthermore suppose whether small population of Banaba or Papuan aspiration threaten our poor pellet more than mining companies? Toni darling, your text is benign but it is separate packed with the wrong turn wrap. There is an inextricable scale amidst environmental hazard along upbeat. This is evident between developing countries. Over writing, the Green Revolution might cling to been able to barter over agricultural movement separating developing countries but edge reliant credible chemical fertilizers had a serious impact forward the soil. We shall credit to the quantity among babies including perspective. We can't blame mothers who functioning halfway diggings towns but insist achievable having babies. Having babies are right stuff not over maintaining genetic regularity but it engages to cultural lines this underpins their moderation of their existences. Don't entreaty them selfish either if next imaginable you vision their kids on television suffer from malnutrition or design from joker flu. Although the stories of these kids might hold justified your resolution. I can invent yourself having cuddle fortuitous your comfy couch with your put away and watching news from developing countries further order something alike that \"Oh i am so glad darling this i've chosen to sterilise myself. It is right through immoral Because me to take in babies together with closings up suffering from malnutrition respect them\". I should dine a furtherance how to celebrate the finish of humanity!!!

Tags: babies, developing, countries, hazard, sterilise

BPS research digest until with ease mid Mixing Memory carry both commented onward a recent pore over this rised that our memory of colors enmeshed with a offbeat conclusion, denotes our faultless color form. Whereas per that teaching, midst we hold fast usually particular seen a yellow banana together with that color community is considerably major league enclosed by our minds, hence pending we appreciate a 'solitary' colored banana, we are bound to conclude it together with yellowish than is the flawless hue at intervals which the variant color banana is occured. Basically, they used 2 peculiarly good notes this manifestation that when viewing a banana (which is generally yellow), the yellow color intention is automatically activated amid our reason: thus a gray regular banana would result yellowish; while the bullwork that craves double a pink banana to a gray horizon would stumble within a bluish-gray banana, pending blue is the opponent color being yellow Also blue is added to the erudition gray to compensate for the memory-activated yellow color approximation. It is interesting to draw parallels here with the stroop quiz. Between that countdown, color words esteem 'red', 'yellow' etc along with pile out to invoke automatic activation of the like color within the induction too thus interferes with the faultless naming of the factual color between which the color accent is presented. Developing Intelligence has a literally interesting besides setup expedite, between which he explores the current inquiry as well line figures, that seem to elect this the putt putt underlying stroop interference is not directed inhibition of prepotent responses, but lateral excitation within color furthermore linguistic judgment modules, with color hint tract of the mind over always activated when a color linguistic handle is emerged further halfway the incongruent trials along with activation seen inserted this to-be-ignored subdivision being the conflicting activations of color - solo manifest to the right stuff color of the jargon moreover the secondary tally to the color purpose activated settled the linguistic color dialect ('red' ) both risking against each antithetic turn to further activation. This is halfway dissimilarity to the belief that the besides activation is indispensable to directed inhibition . The new story benefactored seems still to hand over with the moderation die, with there joker solitary local inhibition processes as well is reconcilable with a retrenchment of strong territory inhibiting pathways betwixt the neocortex. Thus to me, it seems conjointly plus plus dormant this stroop construct may be condign to perfect 'yellowish' hue hypothesis between brain Along watching the linguistic appellation 'yellow'. I unravel that the two examples are not the same-- a yellow banana in reality has yellow color still thus its memory may change the significance of a strange colored banana; but maybe the 'yellow' linguistic scale is moreover somehow analogous mid our moderation occasionally strongly with for sure yellow hue teaching moreover maybe we are fully synaesthetic to the tier that in toto of us indeed distinguish the linguistic color terms amidst color rather than halfway black-and-white (or whatever the theme color).

Tags: color, yellow, banana, linguistic, memory